Literature DB >> 24528781

Psychopathology in adults with 22q11 deletion syndrome and moderate and severe intellectual disability.

L J M Evers1, T A M J van Amelsvoort, M J J M Candel, H Boer, J J M Engelen, L M G Curfs.   

Abstract

BACKGROUND: 22q11 deletion syndrome (22q11DS) is associated with mild or borderline intellectual disability (ID). There are hardly any reports on subjects with 22q11DS with moderate or severe ID, and therefore its behavioural and psychiatric characteristics are unknown.
METHOD: We describe behavioural and psychiatric characteristics of 33 adults with 22q11DS and a Full-Scale IQ (FSIQ) below 55. Participants were divided into two groups: one group having a FSIQ ≤ 55 caused by intellectual decline (n = 21) and one group with a FSIQ ≤ 55 who had always functioned at this level (n = 12).
RESULTS: High scores on psychopathology sub-scales were found for both subgroups. 22q11DS patients with intellectual decline showed higher rates of co-morbid psychopathology, particularly psychosis. Furthermore, psychosis and intellectual decline were positive correlated.
CONCLUSION: This is the first report addressing adult patients with 22q11DS and moderate to severe ID. Overall we found high levels of psychopathology with higher scores of psychopathology in the intellectual decline group. Life time psychosis seems to be related to deterioration.
© 2014 MENCAP and International Association of the Scientific Study of Intellectual and Developmental Disabilities and John Wiley & Sons Ltd.

Entities:  

Keywords:  22q11 deletion syndrome; IQ; intellectual decline; psychopathology; velocardiofacial syndrome

Mesh:

Year:  2014        PMID: 24528781     DOI: 10.1111/jir.12117

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  15 in total

Review 1.  Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series.

Authors:  Nancy J Butcher; Erik Boot; Anthony E Lang; Danielle Andrade; Jacob Vorstman; Donna McDonald-McGinn; Anne S Bassett
Journal:  Am J Med Genet A       Date:  2018-05-19       Impact factor: 2.802

2.  PRODH rs450046 and proline x COMT Val¹⁵⁸ Met interaction effects on intelligence and startle in adults with 22q11 deletion syndrome.

Authors:  Mariken B de Koning; Esther D A van Duin; Erik Boot; Oswald J N Bloemen; Jaap A Bakker; Kathryn M Abel; Thérèse A M J van Amelsvoort
Journal:  Psychopharmacology (Berl)       Date:  2015-06-12       Impact factor: 4.530

3.  The use of two different MLPA kits in 22q11.2 deletion syndrome.

Authors:  L J M Evers; J J M Engelen; L M H Houben; L M G Curfs; T A M J van Amelsvoort
Journal:  Eur J Med Genet       Date:  2016-02-24       Impact factor: 2.708

Review 4.  Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome.

Authors:  Ania M Fiksinski; Maude Schneider; Clodagh M Murphy; Marco Armando; Stefano Vicari; Jaume M Canyelles; Doron Gothelf; Stephan Eliez; Elemi J Breetvelt; Celso Arango; Jacob A S Vorstman
Journal:  Am J Med Genet A       Date:  2018-09-08       Impact factor: 2.802

5.  Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome.

Authors:  Erik Boot; Nancy J Butcher; Thérèse A M J van Amelsvoort; Anthony E Lang; Connie Marras; Margarita Pondal; Danielle M Andrade; Wai Lun Alan Fung; Anne S Bassett
Journal:  Am J Med Genet A       Date:  2015-02-13       Impact factor: 2.802

6.  Neuropsychiatric aspects of 22q11.2 deletion syndrome: considerations in the prenatal setting.

Authors:  Anne S Bassett; Gregory Costain; Christian R Marshall
Journal:  Prenat Diagn       Date:  2016-11-14       Impact factor: 3.050

Review 7.  22q11.2 deletion syndrome.

Authors:  Donna M McDonald-McGinn; Kathleen E Sullivan; Bruno Marino; Nicole Philip; Ann Swillen; Jacob A S Vorstman; Elaine H Zackai; Beverly S Emanuel; Joris R Vermeesch; Bernice E Morrow; Peter J Scambler; Anne S Bassett
Journal:  Nat Rev Dis Primers       Date:  2015-11-19       Impact factor: 52.329

8.  The impact of hypocalcemia on full scale IQ in patients with 22q11.2 deletion syndrome.

Authors:  Katheryn Grand; Lorraine E Levitt Katz; T Blaine Crowley; Edward Moss; Megan Lessig; Vaneeta Bamba; Katherine Lord; Elaine H Zackai; Beverly S Emanuel; Kathleen Valverde; Donna M McDonald-McGinn
Journal:  Am J Med Genet A       Date:  2018-10       Impact factor: 2.802

9.  Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome.

Authors:  Jacob A S Vorstman; Elemi J Breetvelt; Sasja N Duijff; Stephan Eliez; Maude Schneider; Maria Jalbrzikowski; Marco Armando; Stefano Vicari; Vandana Shashi; Stephen R Hooper; Eva W C Chow; Wai Lun Alan Fung; Nancy J Butcher; Donald A Young; Donna M McDonald-McGinn; Annick Vogels; Therese van Amelsvoort; Doron Gothelf; Ronnie Weinberger; Abraham Weizman; Petra W J Klaassen; Sanne Koops; Wendy R Kates; Kevin M Antshel; Tony J Simon; Opal Y Ousley; Ann Swillen; Raquel E Gur; Carrie E Bearden; René S Kahn; Anne S Bassett
Journal:  JAMA Psychiatry       Date:  2015-04       Impact factor: 21.596

Review 10.  Practical guidelines for managing adults with 22q11.2 deletion syndrome.

Authors:  Wai Lun Alan Fung; Nancy J Butcher; Gregory Costain; Danielle M Andrade; Erik Boot; Eva W C Chow; Brian Chung; Cheryl Cytrynbaum; Hanna Faghfoury; Leona Fishman; Sixto García-Miñaúr; Susan George; Anthony E Lang; Gabriela Repetto; Andrea Shugar; Candice Silversides; Ann Swillen; Therese van Amelsvoort; Donna M McDonald-McGinn; Anne S Bassett
Journal:  Genet Med       Date:  2015-01-08       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.